

US Family Health Plan
 Prior Authorization Request Form for
Ixekizumab (Taltz)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:
Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Clinical documentation may be required for approval.

Step 1 Please complete patient and physician information (please print):

Patient Name: _____ Address: _____ Sponsor ID #: _____ Date of Birth: _____	Physician Name: _____ Address: _____ Phone #: _____ Secure Fax #: _____
--	--

Step 2 Please complete the clinical assessment:

1. What is the patient's age?	<input type="checkbox"/> 18 years of age or older – proceed to question 2 <input type="checkbox"/> 6 years of age to less than 18 years of age – proceed to question 3 <input type="checkbox"/> Younger than 6 years of age – STOP Coverage not approved	
2. What is the indication or diagnosis in this adult patient?	<input type="checkbox"/> Active psoriatic arthritis – proceed to question 4 <input type="checkbox"/> Moderate to severe plaque psoriasis in a patient who is a candidate for systemic therapy or phototherapy. – proceed to question 4 <input type="checkbox"/> Active ankylosing spondylitis (AS) – proceed to question 4 <input type="checkbox"/> Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation – proceed to question 4 <input type="checkbox"/> Other indication or diagnosis – STOP Coverage not approved.	
3. What is the indication or diagnosis in this pediatric patient?	<input type="checkbox"/> Moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy – proceed to question 4 <input type="checkbox"/> Other indication or diagnosis – STOP Coverage not approved.	
4. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	<input type="checkbox"/> Yes proceed to question 5	<input type="checkbox"/> No proceed to question 7

5. Has the patient had an inadequate response to Humira?	<input type="checkbox"/> Yes proceed to question 8	<input type="checkbox"/> No proceed to question 6
6. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes proceed to question 8	<input type="checkbox"/> No proceed to question 7
7. Does the patient have a contraindication to Humira (adalimumab)?	<input type="checkbox"/> Yes proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved
8. Has the patient tried and experienced an inadequate response to Cosentyx (secukinumab)?	<input type="checkbox"/> Yes proceed to question 11	<input type="checkbox"/> No proceed to question 9
9. Has the patient experienced an adverse reaction to Cosentyx (secukinumab) that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes proceed to question 11	<input type="checkbox"/> No proceed to question 10
10. Does the patient have a contraindication to Cosentyx (secukinumab)?	<input type="checkbox"/> Yes proceed to question 11	<input type="checkbox"/> No STOP Coverage not approved
11. What is the requested medication being used for?	<input type="checkbox"/> Ankylosing spondylitis (AS) – proceed to question 12 <input type="checkbox"/> Non-radiographic axial spondyloarthritis (nr-axSpA) – proceed to question 12 <input type="checkbox"/> Other indication or diagnosis – proceed to question 13	
12. Has the patient had an inadequate response to at least two NSAIDs over a period of at least two months?	<input type="checkbox"/> Yes proceed to question 17	<input type="checkbox"/> No STOP Coverage not approved
13. Has the patient tried and experienced an inadequate response to Stelara (ustekinumab)?	<input type="checkbox"/> Yes proceed to question 16	<input type="checkbox"/> No proceed to question 14
14. Has the patient experienced an adverse reaction to Stelara (ustekinumab) that is not expected to occur with the requested agent?	<input type="checkbox"/> Yes proceed to question 16	<input type="checkbox"/> No proceed to question 15
15. Does the patient have a contraindication to Stelara (ustekinumab)?	<input type="checkbox"/> Yes proceed to question 16	<input type="checkbox"/> No STOP Coverage not approved
16. Has the patient had an inadequate response to non-biologic systemic therapy? (For example: methotrexate, aminosalicylates [such as, sulfasalazine, mesalamine], corticosteroids, immunosuppressants [for example., azathioprine], etc.)	<input type="checkbox"/> Yes proceed to question 17	<input type="checkbox"/> No STOP Coverage not approved

17. Does the patient have evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?	<input type="checkbox"/> Yes proceed to question 18	<input type="checkbox"/> No STOP Coverage not approved
18. Will the patient be receiving other targeted immunomodulatory biologics with the requested medication including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Rinvoq ER, Rituxan, Siliq, Simponi, Skyrizi, Stelara, Tremfya or Xeljanz/Xeljanz XR?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Sign and date below

Step 3 I certify the above is true to the best of my knowledge. Please sign and date:

_____ Prescriber Signature

_____ Date

[02 Oct 2024]